News Archive

Sept. 28, 2023 — Cardiovascular disease is the number one killer of people in the United States and worldwide.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no clinical benefit to taking fluticasone furoate for treatment of mild-to-moderate COVID-19 symptoms.

CardioHealth Alliance is announcing a new project sponsored by Amgen aimed at assessing and gathering data regarding how to improve quality of care among patients hospitalized for ASCVD. This work, referred to as the “Test to Treat” project, will be led by cardiovascular disease prevention specialist and DCRI faculty member Neha Pagidipati, MD, MPH.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for 13 days for the treatment of mild-to-moderate COVID-19 symptoms.

A group of promising young scientists completed the ninth annual Duke STAR Program in August, after spending the summer building research skills and working side-by-side with Duke University faculty to research medications and how they are being used.

Researchers have developed a blood test that detects Parkinson’s disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens.

The first cohort of Duke Clinical Research Institute’s newest internship program, the Science of Diversity in Clinical Trials (SDCT), celebrated the conclusion of the program by presenting the importance of community engagement in clinical research, lessons learned, and their personal journeys to the program’s faculty and staff and partners in July.

Despite numerical improvements in mortality, hospitalizations and exercise ability, data did not reach the pre-specified level of statistical significance.

Newly published research led by the Pediatrix Medical Group and the Duke Clinical Research Institute’s Rachel Greenberg, MD, MB, MHS assessed the impact of COVID-19 on pregnant women and infants admitted to the neonatal intensive care unit (NICU). It is believed to be the largest study evaluating the prevalence of COVID-19 within a diverse neonatal population and associated hospital outcomes.

The design of the clinical trials will allow comparison of multiple interventions across symptom areas for people living with long COVID.